Sidoti Estimates Prenetics Global’s Q3 Earnings (NASDAQ:PRE)

Prenetics Global Limited (NASDAQ:PRE) – Stock analysts at Sidoti reduced their Q3 2026 earnings per share estimates for Prenetics Global in a research report issued on Wednesday, July 15th. Sidoti analyst A. Hantman now anticipates that the company will post earnings per share of ($0.85) for the quarter, down from their previous estimate of ($0.48). The consensus estimate for Prenetics Global’s current full-year earnings is ($1.26) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2026 earnings at ($0.95) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.01) EPS, Q4 2027 earnings at $0.16 EPS and FY2027 earnings at ($0.60) EPS.

Prenetics Global (NASDAQ:PRE) last issued its quarterly earnings data on Wednesday, June 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.07). The company had revenue of $35.95 million for the quarter, compared to analysts’ expectations of $36.00 million. Prenetics Global had a negative net margin of 62.45% and a negative return on equity of 20.33%.

A number of other brokerages also recently issued reports on PRE. Benchmark raised their price target on Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research note on Tuesday, April 21st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.25.

Prenetics Global Stock Performance

NASDAQ PRE opened at $18.29 on Friday. The company has a market cap of $308.55 million, a P/E ratio of -3.99 and a beta of 0.26. The business’s 50 day moving average price is $18.70 and its 200-day moving average price is $18.47. Prenetics Global has a fifty-two week low of $7.18 and a fifty-two week high of $23.63.

Hedge Funds Weigh In On Prenetics Global

Several hedge funds have recently bought and sold shares of PRE. Wells Fargo & Company MN purchased a new stake in Prenetics Global in the fourth quarter worth $47,000. State of Wyoming purchased a new stake in shares of Prenetics Global during the first quarter valued at $48,000. JPMorgan Chase & Co. purchased a new stake in shares of Prenetics Global during the third quarter valued at $65,000. Manatuck Hill Partners LLC bought a new position in shares of Prenetics Global in the fourth quarter worth about $170,000. Finally, T3 Companies LLC bought a new position in shares of Prenetics Global in the fourth quarter worth about $170,000. Institutional investors own 25.01% of the company’s stock.

Key Prenetics Global News

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: Prenetics said its IM8 business secured $1 billion in non-dilutive financing, which could support growth without issuing new shares and signals strong outside confidence in the subsidiary’s outlook. Prenetics’ IM8 Secures $1 Billion Non-Dilutive Financing as Revenue Outlook Rises
• Positive Sentiment: Management also highlighted that PRE continues to exceed expectations and is receiving preferential financing, reinforcing the idea that the company may have better operating momentum than the market had assumed. PRE Continues to Exceed Expectations and Receive Preferential Financing
• Positive Sentiment: CEOs comments about using the financing to fuel IM8’s growth suggest the company has a clearer path to scaling a high-growth subsidiary, which can improve investor sentiment around future revenue expansion. Prenetics CEO on securing 1 billion funding to fuel subsidiary IM8’s growth
• Neutral Sentiment: Sidoti and other analysts maintained a generally constructive stance overall, with a consensus recommendation of “Moderate Buy,” but the reports mostly focused on model updates rather than a major new catalyst. Prenetics Global Limited (NASDAQ:PRE) Given Consensus Recommendation of Moderate Buy by Analysts
• Negative Sentiment: Sidoti cut earnings estimates for several periods, including 2026-2027 quarters and FY2027, which could weigh on the stock because it implies weaker near-term profitability than previously expected.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.